- Home
- CNSP vs CURX Comparison
CNSP vs CURX Comparison
Compare CNSP & CURX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNSP | CURX |
|---|---|---|
| Founded | 2017 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 7.5M |
| IPO Year | 2019 | 2024 |
Fundamental Metrics
Financial Performance| Metric | CNSP | CURX |
|---|---|---|
| Price | $4.75 | $4.88 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.3K | ★ 20.0K |
| Earning Date | 11-16-2026 | 09-09-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.03 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.90 | $0.21 |
| 52 Week High | $10.54 | $16.93 |
Technical Indicators
Market Signals| Indicator | CNSP | CURX |
|---|---|---|
| Relative Strength Index (RSI) | 37.40 | 60.85 |
| Support Level | $4.68 | $5.24 |
| Resistance Level | $5.52 | $6.00 |
| Average True Range (ATR) | 0.25 | 0.50 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 50.66 | 89.06 |
Price Performance
Historical ComparisonAbout CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.
About CURX Curanex Pharmaceuticals Inc
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant.